至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

A novel ultrasensitive assay for plasma p-tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease

Alzheimers Dement. 2023-11; 
Fernando Gonzalez-Ortiz, Pamela C L Ferreira, Armand González-Escalante, Laia Montoliu-Gaya, Paula Ortiz-Romero, Przemyslaw R Kac, Michael Turton, Hlin Kvartsberg, Nicholas J Ashton, Henrik Zetterberg, Peter Harrison, Bruna Bellaver, Guilherme Povala, Victor L Villemagne, Tharick A Pascoal, Mary Ganguli, Anne D Cohen, Carolina Minguillon, Jose Contador, Marc Suárez-Calvet, Thomas K Karikari, Kaj Blennow
Products/Services Used Details Operation

摘要

background: Detection of Alzheimer's disease (AD) pathophysiology among individuals with mild cognitive changes and those experiencing subjective cognitive decline (SCD) remains challenging. Plasma phosphorylated tau 217 (p-tau217) is one of the most promising of the emerging biomarkers for AD. However, accessible methods are limited. methods: We employed a novel p-tau217 immunoassay (University of Gothenburg [UGOT] p-tau217) in four independent cohorts (n = 308) including a cerebrospinal fluid (CSF) biomarker-classified cohort (Discovery), two cohorts consisting mostly of cognitively unimpaired (CU) and mild cognitively impaired (MCI) participants (MYHAT and Pittsburgh), and a population-based cohort of ind... More

关键词

Alzheimer's disease, blood biomarkers, early diagnosis, p-tau217, preclinical, subjective cognitive decline